公开(公告)号：EP2222220B1

公开(公告)日：2016-03-16

申请号：EP08857358.9

申请日：2008-12-05

申请人： THE CLEVELAND CLINIC FOUNDATION

发明人： HAZEN, Stanley, L. ,  WANG, Zeneng ,  LEVISON, Bruce, S.

IPC分类号： A61B5/00 ,  G01N33/92

CPC分类号： G01N33/49 ,  G01N33/493 ,  G01N33/6893 ,  G01N33/92 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/56 ,  H01J49/0036 ,  Y10T436/174614

公开(公告)号：EP2222220A1

公开(公告)日：2010-09-01

申请号：EP08857358.9

申请日：2008-12-05

申请人： The Cleveland Clinic Foundation

发明人： HAZEN, Stanley, L. ,  WANG, Zeneng ,  LEVISON, Bruce, S.

IPC分类号： A61B5/00

CPC分类号： G01N33/49 ,  G01N33/493 ,  G01N33/6893 ,  G01N33/92 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/56 ,  H01J49/0036 ,  Y10T436/174614

摘要： Methods of characterizing a test subject's risk of having or developing cardiovascular disease are provided. The methods include using an analytic device to determine levels of choline-related trimethylamine-containing compounds such as trimethylamine N-oxide, choline, or betaine in a biological sample obtained from the subject and comparing the levels of the choline-related trimethylamine-containing compound in the subject's biological sample to a control value. The test subject's risk of having cardiovascular disease is then characterized as higher if the levels of the choline-related trimethylamine-containing compound are higher than the control value. Also provided are methods of identifying a subject at risk of experiencing a complication of atherosclerotic cardiovascular disease, and methods of evaluating the efficacy of a cardiovascular therapeutic agent in a subject with cardiovascular disease using levels of choline-related trimethylamine-containing compounds.

摘要翻译： 提供表征测试受试者患有或发展心血管疾病的风险的方法。 该方法包括使用分析装置来测定从受试者获得的生物样品中胆碱相关的含三甲胺的化合物（例如三甲胺N-氧化物，胆碱或甜菜碱）的水平，并比较含胆碱相关的含三甲胺化合物 在受试者的生物样品中达到对照值。 如果含有胆碱相关三甲胺的化合物的水平高于对照值，那么测试对象患心血管疾病的风险被表征为更高。 还提供了鉴定处于动脉粥样硬化性心血管疾病并发症风险中的受试者的方法，以及使用与胆碱有关的含三甲胺化合物的水平评估心血管疾病受试者中心血管治疗剂功效的方法。